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Background: Chronic exposure to arsenic is associated with neoplastic, cardiovascular, endocrine, neuro-developmental
disorders and can have an adverse effect on women’s reproductive health outcomes. This study examined the
relationship between arsenic skin lesions (a hallmark sign of chronic arsenic poisoning) and age of natural menopause
(final menopausal period) in populations with high levels of arsenic exposure in Bangladesh.
Methods: We compared menopausal age in two groups of women – with and without arsenic skin lesions; and
presence of arsenic skin lesions was used as an indicator for chronic arsenic exposure. In a cross-sectional study, a total
of 210 participants were randomly identified from two ongoing studies— participants with arsenic skin lesions were
identified from an ongoing clinical trial and participants with no arsenic skin lesions were identified from an ongoing
cohort study. Mean age of menopause between these two groups were calculated and compared. Multivariable linear
regression was used to estimate the relationship between the status of the arsenic skin lesions and age of natural
menopause in women.
Results: Women with arsenic skin lesions were 1.5 years younger (p <0.001) at the time of menopause compared to
those without arsenic skin lesions. After adjusting with contraceptive use, body mass index, urinary arsenic level and
family history of premature menopause, the difference between the groups’ age at menopause was 2.1 years earlier
(p <0.001) for respondents with arsenic skin lesions.
Conclusions: The study showed a statistically significant association between chronic exposure to arsenic and age at
menopause. Heavily exposed women experienced menopause two years earlier than those with lower or no
exposure.
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Chronic inorganic arsenic poisoning has been characte-
rized by cutaneous abnormalities which includes mela-
nosis (hyperpigmentation) and keratosis [1]. Bangladesh
retained WHO’s previous guideline value for arsenic
concentration in drinking water as a national standard
which suggests 50 μg/L or lesser amount as safe [2], al-
though the current WHO guideline value suggests it as
10 μg/L or less [3]. However, in Bangladesh, out of a
total population of 164 million, around 22 million people
are drinking water with arsenic concentration >50 μg/L,
and, of them, 5.6 million people are drinking water with* Correspondence: dryunus155@gmail.com
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unless otherwise stated.arsenic concentrations even > 200 μg/L [4]. Ground
water arsenic contamination is the largest mass poison-
ing in the history of Bangladesh [5]. Several researchers
found that chronic exposure to high concentrations of
arsenic causes both carcinogens and non-carcinogenic
effects [6-9]. This effect includes arsenical skin lesions
i.e. melanosis and keratosis, vascular diseases, liver and
neurotoxicity, chronic cough, diabetes mellitus, adverse
pregnancy outcomes, and impaired child development.
Arsenic exposure elevates risks of cancer, which persists
even decades after exposure has ceased [10].
Previous studies reported the effect of chronic arsenic
exposure on reproductive health outcomes in women
and noted significant association with adverse pregnancy
outcomes such as spontaneous abortion, stillbirth and
preterm births. Arsenic toxicity may also increases riskstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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arsenic exposure a female reproductive toxicant, and as
an endocrine disruptor, therefore, considered as a major
threat for female reproductive health. In animal (rat) ex-
periments, arsenic toxicity deprives oestrogen receptors
[15] resulting in interrupted normal activity of organs
such as uterine lining, skin, breast tissue, etc. that are re-
sponsible for menopause. Oestrogen is responsible for
the onset of menstruation in adolescents; however grad-
ual deprivation of receptor eventually results early
menopause [16]. In relation to this, another study sug-
gested that arsenic causes delayed menarche [17].
Considering both human and animal studies, this
study hypothesized that chronic arsenic exposure char-
acterized by the presence of arsenic skin lesions could
have a relationship with the natural menopausal age.
This may mean that arsenic associated with early or de-
layed menopause - in either way, this could be an un-
desirable outcome. If menopause occurs early, there will
be a reduction in reproductive period that means
women would likely to experience of cardiovascular dis-
eases, neurological diseases, osteoporosis and psychiatric
diseases earlier in their lives [18]. On the other hand, de-
layed menopause may increase the risk of breast and
ovarian cancers due to their prolonged exposure to
oestrogen [19].
Methods
Study area and population
The study was conducted in Laksam upazilla of Comilla
district, and Araihazar upazilla of Narayangonj district in
Bangladesh. Participants with arsenic skin lesions were
selected from Laksam upzilla as this area is highly con-
taminated to arsenic [20]. Participants without arsenic
skin lesions were selected from Araihazar, another arsenic
contaminated area. Though we collected participants from
two different areas, socio-demographic characteristics
were similar as both are located in the eastern part of
Bangladesh.
Participants with arsenic skin lesions were selected
randomly using the database from an ongoing rando-
mized clinical trial “Bangladesh Vit-E and Selenium Trial
(BEST)” (ClinicalTrails.gov:NCT00392561) conducted in
Laksam, Comilla. This clinical trial aims to determine
the supplementation of vitamin E, selenium or their
combination that could have beneficial effects on arsenic
induced skin cancer. It is a double blind, randomized,
placebo-controlled 2 × 2 factorial clinical trial conducted
among 7,000 individuals with pre-malignant skin lesions
for the prevention of cancers and deaths in Bangladesh.
This study enrolled both male and female participants
with arsenic skin lesions i.e. melanosis and keratosis
within the age limit of 25–65 years. In a recent publica-
tion using the baseline data of this clinical trial,associations was found between arsenical skin lesions
with common chronic diseases such as hypertension,
diabetes, asthma, and peptic ulcer disease [21]. While
participants with non-arsenic skin lesions were selected
randomly from the ongoing cohort database. This pro-
spective cohort study “Health Effects of Arsenic Longitu-
dinal Study (HEALS)” aims to investigate the intermediate
and long-term pre-malignant, malignant and non-
malignant health effects of among ~30,000 men and
women who were naturally exposed with arsenic through
drinking water. This cohort enrolled both male and female
participants with a history of drinking water at least three
years from the same tube-well within the age limit of 18–
75 years. Mean urinary arsenic concentrations of male
(140 μg/L) and female (136 μg/L) participants were found
in the baseline survey [22]. Both of these databases en-
rolled participants in 2006 and 2007. Finally, participants
for this study were randomly selected based on two basic
criteria- one was women with a presence or absence of ar-
senic skin lesions, and another was women, who had ex-
perienced menopause within the last five years (from
2011) with the age limit of 35–55 years.
Considering 80% power, 5% level of significance, Un-
exposed/Exposed ratio of 1, percent of unexposed with
outcome 30 and percent of exposed with outcome 50
using the “OpenEpi” version 2.2 software (Developer:
Emory University, Rollins School of Public Health) the
sample size was calculated [23]. This yielded a total
number of 190 participants, among them 95 were ex-
posed and 95 were unexposed to arsenic. Finally a total
210 eligible women were interviewed to collect relevant
information using the “recall” method. Among them,
105 participants had arsenic skin lesions and 105 partici-
pants did not. Using the range of eligibility from 35 to
51 years yielded a total of 187 participants for further
analysis out of total interviewed 210 participants.
Among the selected participants, 95 had arsenic skin
lesions and 92 had no arsenic skin lesions.
Data collecting procedure
Detail menopausal history and socio-demographic infor-
mation was collected using close-ended structured ques-
tionnaires consisting of easy-to-understand questions
with appropriate response options. The researchers de-
veloped the questionnaire and pretested in a neigh-
bouring village similar to the study area.
Ten trained female staffs were recruited for this study
as interviewers. They conducted a door-to-door survey
to identify the potential participants from the randomly
selected list of those databases. All staff were from the
study areas and had a very good cultural understanding
of the participants. Moreover, interviewers were kept
blinded to the objectives of the study. Questionnaires
were read and comprehensively explained in front of the
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participate in the study, they were then asked to sign or
put a thumbprint on the written informed consent
paper. For both groups, interviewers back-checked the
presence or absence of arsenical skin lesions i.e. melan-
osis, leucomelanosis and keratosis by full body examin-
ation under sunlight. Before the final enrollment into
the study, screening was done on under certain criteri-
ons such as current menstruation, menopause occurred
in less than 1 year (in order to get the final menstrual
period) or menopause occurred in more than 5 years,
history of using depot injection in last five years, con-
ducted total abdominal hysterectomy (TAH), bilateral
salpingo-oophorectomy and severe medical conditions.
Finally, women were asked to recall their menopausal
age. It was assumed that they could recall accurately as
it an important life event for women.
Exposure assessment
Arsenic exposure was determined through the presence
or absence of arsenic skin lesions. This is because skin
lesions are a hallmark sign of chronic arsenic poisoning—
hyperkeratosis and melanosis are considered as an indica-
tor of high arsenic exposure [24,25] whereas urinary
arsenic level indicates recent exposure within a few days
of the specimen collection [26].
Outcome assessment
Natural menopause was determined according to the
World Health Organization (WHO) definition “Perman-
ent cessation of menstruation resulting from the loss of
ovarian follicular activity” which corresponds to a single
point in time- the final menstrual period (FMP) [27].
This study used the final menstrual period as an out-
come variable.
Covariate and other variables
Several studies suggest that a number of factors may
affect natural menopausal age, such as smoking, educa-
tional attainment, income, marital status, employment,
parity, contraceptive use, family history of premature
menopause, cancer and history of chemotherapy or
radiotherapy and body mass index [18,28-35]. Among
these, a few factors such as smoking, parity, marital sta-
tus, income, use of contraceptive methods, body mass
index and family history of premature menopause pre-
vailed among the respondents. Socio-demographic infor-
mation such as number of children, education, marital
status, monthly household income was collected. Other
than these, detailed menstrual information such as age
of menarche, age of menopause, menstrual regularity
and its frequency, use of contraceptives, and family his-
tory of premature menopause were also collected. To
obtain the family history of premature menopause,participants were asked whether their mother or sister
had experienced menopause before the age of 40 years
[28]. Information related to arsenic such as duration of
exposure to arsenic and urinary arsenic level were taken
from two databases of clinical trial and cohort study in
the year of 2006–2007. Other factors that may affect the
age of menopause such as smoking history and body
mass index (BMI) were reviewed retrospectively. BMI
was calculated using the standard method (weight in kg/
height in meter2) [36]. The reason behind reviewing in-
formation from the mentioned database (2006–2007)
was to explore other factors at the time of menopause.
Statistical analysis
Both descriptive and inferential analysis was done by
using SPSS software- version 17 (Chicago, IL), and
Microsoft Excel (2010). Frequency tables and summary
statistics were done to check the missing data, out of
range values and to assess distributions of continuous
variables, and logic checks were done. Independent-
sample t tests were undertaken to compare the mean
difference of age of menarche, age of menopause and re-
productive period between participants with and without
arsenic skin lesions. Reproductive period was calculated
by deducting the age of menarche from the age of
menopause.
Multivariable linear regressions were done to estimate
the relationship between arsenic skin lesions and age of
menopause after adjusting for potential confounding
variables. Initially univariate analyses such as chi-square
tests were done to explore the association between the
two groups of participants, their socio-demographic
characteristics such as age, occupation, monthly house-
hold income, education, marital status, menstrual regu-
larity and frequency (that they experienced in the past)
and with the potential factors that affect the age of
menopause. These factors, such as smoking, family his-
tory of premature menopause, number of children, BMI,
use of contraceptives and urinary arsenic level (μg/g cre-
atinine) were included in the initial model. In the final
regression model, only significant covariates were in-
cluded. Categorical variables were entered in the final
model as dummy variables.
Ethical review
The study protocol and recruitment procedure (access
to the databases) were approved by the Ethical Review
Board of the James P Grant School of Public health,
BRAC University as per the existing rules.
Results
Participants background, detail menopausal information
and association between groups are presented in Table 1.
Mean age (±SD) of the respondents was 48.0 (±3.6)
Table 1 Distribution of socio-demographic characteristics and menstrual details of the study population by arsenic skin
lesions
Variables N % Arsenic skin lesions
Yes (N = 95) No (N = 92) Mean difference p
Age (years); Mean ± SD 48.00 ± 3.64 - 47.14 ± 3.48 48.89 ± 3.60 1.74 .001
Occupation
Housewife 184 98.4 93 91 - .22
Daily Labour 2 1.1 2 0
Govt Service 1 0.5 0 1
Monthly household 9019 (8000) BDT - 9476 (7000) BDT 8549 (4000) BDT 927 BDT .28
Income (BDT, US$); Mean (median) 116 (102) US$ 122 (90) US$ 110 (51) US$ 12 US$
Education
No formal education 114 61.0 53 61 - .07
Primary completed 68 36.4 41 27
Secondary completed 5 2.7 1 4
Marital status
Single 2 1.1 2 0 - .51
Married 165 88.2 83 82
Widowed 16 8.6 8 8
Separated 3 1.6 2 1
Divorced 1 0.5 0 1
Menstrual regularity
Yes 168 89.8 86 82 - .81
No 19 10.2 9 10
Menstrual Frequency
Twice a month 2 1.1 1 1 - .30
Once a month 169 90.4 88 81
Once in every 2 months 10 5.3 3 7
Once in every 3 months 4 2.1 3 1
Once in >3 months 2 1.1 0 2
Arsenic skin lesions duration
4 2.1 4 0 - -<10 years
>10 years 91 48.7 91 0
Age of Menarche; Mean ± SD 14.00 ± 1.36 - 14.17 ± 1.37 13.82 ± 1.33 .355 .069
Age of Menopause; Mean ± SD 44.95 ± 3.35 - 44.17 ± 3.28 45.74 ± 3.25 1.568 .001
Reproductive period; Mean ± SD 30.94 ± 3.51 - 29.99 ± 3.31 31.91 ± 3.48 1.914 .001
Abbreviation: SD Standard Deviation.
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productive age was 14.00 ± 1.36, 44.95 ± 3.35 and 30.94
± 3.51 respectively. The outcome variable ‘age of meno-
pause’ was normally distributed. Most of the participants
were housewife 184 (98.4%). Mean (median) of monthly
household income was 9019(8000) BDT (Bangladeshi
taka) [116 (103) US$]. The majority of women 114 (61%)
had no formal education, 68 (36.4%) women had com-
pleted primary education and only 5 (2.7%) completed
secondary education. Most (165) were married (88.2%).
In terms of menstrual regulation and frequency, most
(168) of the participants (89.8%) had experience ofregular menstruation (i.e. once a month). Out of total
(95) arsenic skin lesions participants, most of them 91
(48.7%) had arsenic skin lesions for more than 10 years.
Among those characteristics, age (p = 0.001) was found
significantly lower in with arsenic skin lesions group
(47.1 ± 3.5) in comparison to without arsenic skin lesions
groups (48.9 ± 3.6). Education (p = 0.07), marital status
(p = 0.51), monthly household income (p = 0.28), men-
strual regularity (p = 0.81) and frequency (p = 0.30) were
not significantly different between groups. Age of me-
narche was similar (p = 0.06) between two groups, how-
ever the menopausal age (p <0.001) and reproductive
Table 3 Relationship between arsenic skin lesions and
age of menopause
Model Coefficientsa p CI 95%
Lower Upper
Contraceptive Use Y/N −.531 .286 −1.510 .449
Arsenic Skin Lesions Y/N −2.102 .001 −3.207 −.996
Body Mass Index (BMI) .002 .977 −.145 .150
Urinary Arsenic Level
(μg/g creatinine)
.002 .075 .000 .004
Family history of premature
menopause (Dummy1- yes)




−.296 .571 −1.326 .734
aOutcome Variable: Age of Menopause.
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the groups. The result indicates 3.5 months delayed age
of menarche and 1.5 years early menopause occurred in
arsenic skin lesions participants compared to partici-
pants without arsenic skin lesions. Approximately,
1.9 years decrease in reproductive period (p = 0.001) oc-
curred among participants with arsenic skin lesions
(29.99 ± 3.31 years) compared to participants without ar-
senic skin lesions (31.91 ± 3.48 years).
Distribution of potential factors such as smoking, fam-
ily history of premature menopause, number of children,
use of contraceptive methods, urinary arsenic level, and
BMI between two groups of participants are presented
in Table 2. Participant’s number of children was nor-
mally distributed and mean (±SD) was 4.74 ± 1.79. Of
the factors, family history of premature menopause (p =
0.001) and use of contraceptives (p = 0.01) were found to
be positively associated between the groups. Continuous
variables such as body mass index (BMI) were found sig-
nificantly lower (p = .03) among women with arsenic
skin lesions (18.93 ± 3.03) in comparison to women
without arsenic skin lesions (19.94 ± 3.48). However,
urinary arsenic levels were found significantly higher (p =
0.001) among individuals with arsenic skin lesions (328.01 ±
284.17) in comparison to individuals without arsenic skin
lesions (156 ± 193.00).
A multivariable linear regression model was under-
taken to adjust all the potential confounders are pre-
sented in Table 3. An overall 2.1 years decrease in
menopausal age was observed (p < 0.001) in women who
had arsenic skin lesions (44.17 ± 3.28) compared to
women without arsenic skin lesions (45.74 ± 3.25) after
adjusting contraceptive use, urinary arsenic level, body
mass index and family history of premature menopause.Table 2 Factors that affect menopausal age
Arsenic skin lesions p
Yes (N = 95) No (N = 92)
Smoking
Previous 1 0 1.00
Never 94 92
Family history of premature
menopause
Yes 17 1 .001
No 43 31
Don’t know 35 60
Number of Children; Mean ± SD 4.74 ± 1.79 4.91 ± 1.79 .52
Contraceptive Used
Yes 47 62 .01
No 48 30
Body Mass Index (BMI) 18.93 ± 3.03 19.94 ± 3.48 .03
Urinary As Level (μg/g creatinine) 328.01 ± 284.17 156 ± 193 .001Discussion
We assessed the relationship of chronic arsenic exposure
(marked by the arsenic skin lesions) and the natural
menopausal age in rural Bangladesh. An overall
3.5 months of delay was observed on the menarcheal
age (p = 0.06) among the participants. Even though this
was not significant, the direction of the difference ob-
served is consistent with other study [17], who assessed
the effect of arsenic on the menarcheal age, and noted a
significant delayed onset of menarcheal age among ado-
lescents exposed to arsenic by drinking tube well water
in West Bengal, India. We did not have reliable data on
their arsenical skin lesions at the time of their menarche,
however, in the context of Bangladesh, it can be easily
assume that all the participants had been drinking the
same arsenic-contaminated water their whole lives as
they had never moved from their community since birth.
Consistent consumption of the contaminated water
gradually led to arsenic poisoning.
Secondly, our finding revealed that chronic arsenic ex-
posure seems to have a relationship with the menopausal
age. Comparing the mean age of menopause between
two groups (with or without arsenic skin lesions), an
overall 1.5 years (p = 0.001) of earlier menopause was
observed among the women who had arsenic skin le-
sions compared to those who did not have arsenic skin
lesions. Mean reproductive period was 1.9 years lower
among the participants with arsenic skin lesions com-
pared to the participants without arsenic skin lesions.
The finding was also similar in the multivariable linear
regression analysis. This result suggests that chronic ex-
posure to arsenic, as marked by the presence of skin le-
sions is associated with early menopause. That means
holding all other potential confounders constant, women
with arsenic skin lesions would experience 2.1 years early
menopause than the women without arsenic skin lesions.
Therefore, these women are at higher risk of developing
non-communicable diseases, including cardiovascular
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atric diseases earlier in their lives compared to the women
without arsenic skin lesions [18]. On the other hand, this
result also indicates that women would be at lower risk of
breast and ovarian cancers due to less duration of expos-
ure to oestrogen [19,37,38]. The current study is, there-
fore, important because it sheds light on the relationship
of high and long-term arsenic exposure on the age of
menopause.
It is not clear how the arsenic metabolism and toxicity
process influences the age of natural menopause in hu-
man. In rat experiments, arsenic has been identified as a
reproductive toxicant and endocrine disruptor, and has
been observed to impact the structure and the functions
of the uterus in female rat [15]. In humans, arsenic in-
teracts with steroids, particularly oestrogen that may
lead to adverse health effects in women. Oestrogen recep-
tors are present in various organs such as uterine lining,
skin, breast tissue, bone and blood vessels. If any of these
organs are deprived of the substrate, menstrual disorders
may result [39]. Arsenic also may cross placental barriers
and exposure to this toxicant may occur when the foetus
is still within the mother’s womb, although its effects may
visibly appear much later in life [37,39].
In this study, all the participants with or without ar-
senic skin lesions have high urinary arsenic level, but the
arsenic skin lesions group showed significantly (p = .001)
higher mean level (328.01 ± 284.17) than their counter-
part (156 ± 193.00). Although the urinary arsenic level is
consider the most reliable method for measuring arsenic
exposure, it is particularly sensitive to recent exposure—
within a few days of the specimen collection [26]. There-
fore, in this study, we deemed skin lesions as the main
criteria for determining arsenic exposure because skin
lesions indicates long-term exposure and this long-term
arsenic exposure is more important to consider for cer-
tain health conditions than recent exposure. Arsenic
skin lesions is also considered as the hallmark sign of
chronic arsenic poisoning and as an indicator of high ar-
senic exposure [24,25].
An important strength of this study was the direct
measurement of arsenic skin lesions in each individual.
Another positive issue was the adjustment for relevant
early menopausal risk factors among the study women
such as number of children, family history of premature
menopause, use of contraceptives, urinary arsenic level
and BMI.As participants (with or without arsenic skin
lesions) were selected randomly, selection bias was less
likely to occur. One potential limitation of the study is
using the self-reported data on the age of menopause
and family history of premature menopause, therefore,
there is a risk of recall bias through differential misclassifi-
cation of natural age of menopause among women with
arsenic lesions. To avoid differential misclassification ofoutcomes, we blinded all study staff that includes inter-
viewers and participants assessing for both exposures to
outcome and outcome to exposures status. Along with
this, we conducted training among the interviewers in
order to adhere to the question, and answer the format
strictly, with the same degree of questioning on objective
measures (hard data) for both with or without arsenic skin
lesions participants to reduce interviewer bias. However,
we assume that any fluctuation of recalling menopausal
age and the family history of premature menopause is
likely to affect equally in participants with or without ar-
senic skin lesions. Another limitation of this study is that
bio-markers for arsenic exposure such as hair, nail and
blood concentration of arsenic were not measured. As this
is a cross-sectional study, temporality between arsenic ex-
posure and menopause cannot be claimed. Prospective co-
hort study with such population could elucidate this
relationship. Although we recruited participants from two
different places, as a proxy for socioeconomic status,
monthly household income was not significantly different
(p = 0.35) among arsenic skin lesions (90 US$)) and with-
out arsenic skin lesions (103 US$) participants.
Conclusions
This study suggests that natural menopausal age has rela-
tionship with chronic arsenic exposure (marked by the
presence of arsenic skin lesions). The study found meno-
pause occurs earlier when women had arsenic skin lesions.
This early experience of menopause results in women hav-
ing an increased risk of suffering from serious diseases
such as cardiovascular, neurological, osteoporosis, and
psychiatric diseases. This study also reveals that women
with arsenic skin lesions experienced shorter reproductive
period in their lifetime. Moreover, evidence connecting
high and long-term arsenic exposure to altered age of
menopause has strengthened the argument that arsenic
directly affects reproductive health. Further research, espe-
cially with a larger sample, could elucidate the interaction
between arsenic exposure, oestrogen hormone, and the
menopausal age. To the best of our knowledge, we did not
find any other study that carried out on the relationship
between arsenic skin lesions and the age of menopause.
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